A. Oliver Sartor, MD

Articles

Dr. Sartor on the Significance of the REASSURE Trial in mCRPC

July 10th 2020

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Dr. Sartor on Outcomes With 177Lu-PSMA-617 After Radium-223 in mCRPC

June 18th 2020

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

Dr. Sartor on Sequential Use of Beta and Alpha Emitters in mCRPC

June 17th 2020

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.

Dr. Sartor on Implications of PSMA-PET Positivity in Prostate Cancer

March 31st 2020

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

Dr. Sartor on Emerging Agents in Prostate Cancer

February 6th 2020

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Dr. Sartor on Promising Treatment Approaches in Prostate Cancer

January 25th 2020

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Dr. Sartor on the VISION Trial in mCRPC

November 16th 2019

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.